Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ALDX
stocks logo

ALDX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.140
-48.15%
--
--
-0.150
-11.76%
--
--
-0.150
-6.25%
Estimates Revision
The market is revising No Change the revenue expectations for Aldeyra Therapeutics, Inc. (ALDX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -12.23%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-10.61%
In Past 3 Month
Stock Price
Go Down
down Image
-12.23%
In Past 3 Month
Wall Street analysts forecast ALDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALDX is 8.67 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast ALDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALDX is 8.67 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.880
sliders
Low
7.00
Averages
8.67
High
10.00
Current: 4.880
sliders
Low
7.00
Averages
8.67
High
10.00
BTIG
Thomas Shrader
Strong Buy
Maintains
$11 → $9
2025-04-07
Reason
BTIG
Thomas Shrader
Price Target
$11 → $9
2025-04-07
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$10
2025-04-04
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$10
2025-04-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Matthew Caufield
Strong Buy
Reiterates
$10
2025-03-03
Reason
HC Wainwright & Co.
Matthew Caufield
Price Target
$10
2025-03-03
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Aldeyra Therapeutics Inc (ALDX.O) is -9.38, compared to its 5-year average forward P/E of -14.82. For a more detailed relative valuation and DCF analysis to assess Aldeyra Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-14.82
Current PE
-9.38
Overvalued PE
15.37
Undervalued PE
-45.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.93
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.67
Undervalued EV/EBITDA
-7.20

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
21.11
Current PS
0.00
Overvalued PS
60.56
Undervalued PS
-18.34
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ALDX News & Events

Events Timeline

(ET)
2025-11-13
07:40:11
Aldeyra Enhances RASP Platform
select
2025-10-28 (ET)
2025-10-28
08:02:24
Aldeyra's ADX-629 Shows Notable Enhancement in Liver Function Results
select
2025-08-28 (ET)
2025-08-28
07:10:50
Aldeyra Granted Orphan Drug Status by EMA for ADX-2191
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-27NASDAQ.COM
Biotech Stocks Await FDA Verdict in December 2025

  • National Influenza Vaccination Week: Observed from December 1-5, this campaign encourages vaccination against the flu, emphasizing its safety and effectiveness, and serves as a reminder that it's never too late to get vaccinated.

  • World AIDS Day: Celebrated on December 1, this global observance raises awareness about HIV/AIDS, honors those lost, and supports those living with the virus, with a focus on political leadership and human rights to end AIDS as a public health threat by 2030.

  • HIV Statistics: In 2024, approximately 40.8 million people were living with HIV, with around 630,000 deaths from HIV-related causes and 1.3 million new infections, highlighting the ongoing impact of the epidemic.

  • Funding Concerns: There are worries about significant cuts to international HIV funding, particularly from the U.S., which has historically contributed nearly 75% of global financing, with recent reductions affecting key commitments and activities related to World AIDS Day.

[object Object]
Preview
9.0
11-13Newsfilter
Aldeyra Therapeutics Expands RASP Platform to Address Central Nervous System Disorders and Shares Reproxalap Updates During Research & Development Webcast

  • Expansion of RASP Platform: Aldeyra Therapeutics announced the expansion of its RASP platform to include programs targeting central nervous system diseases associated with inflammation, based on promising preclinical results for the RASP modulator ADX-248 in models of Parkinson's disease and amyotrophic lateral sclerosis.

  • FDA Inspections Update: The FDA completed routine inspections of Aldeyra's reproxalap manufacturing facilities, resulting in Voluntary Action Indicated (VAI) designations, indicating that no further action is necessary.

  • Future Developments: Aldeyra's CEO highlighted the potential of ADX-248 and other RASP modulators as novel treatments for various clinical indications, expressing optimism for future updates on their therapeutic pipeline.

  • Conference Call Announcement: Aldeyra will host a conference call to discuss new preclinical results and updates on reproxalap, with details available on their Investor Relations website.

[object Object]
Preview
1.0
11-11Newsfilter
Aldeyra Therapeutics to Attend the Jefferies Global Healthcare Conference in London

  • Company Announcement: Aldeyra Therapeutics, Inc. announced that CEO Todd C. Brady will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in London on November 20, 2025.

  • Webcast Details: The conversation will be available for live streaming on Aldeyra's website and will be archived for 90 days after the event.

  • Company Focus: Aldeyra is dedicated to developing innovative therapies for immune-mediated diseases, utilizing a unique approach that modulates protein systems rather than targeting single proteins.

  • Product Candidates: The company is advancing several product candidates, including reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191 for primary vitreoretinal lymphoma and retinitis pigmentosa.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aldeyra Therapeutics Inc (ALDX) stock price today?

The current price of ALDX is 4.88 USD — it has increased 0.21 % in the last trading day.

arrow icon

What is Aldeyra Therapeutics Inc (ALDX)'s business?

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.

arrow icon

What is the price predicton of ALDX Stock?

Wall Street analysts forecast ALDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALDX is 8.67 USD with a low forecast of 7.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aldeyra Therapeutics Inc (ALDX)'s revenue for the last quarter?

Aldeyra Therapeutics Inc revenue for the last quarter amounts to -8.00M USD, decreased -50.42 % YoY.

arrow icon

What is Aldeyra Therapeutics Inc (ALDX)'s earnings per share (EPS) for the last quarter?

Aldeyra Therapeutics Inc. EPS for the last quarter amounts to -7021416.00 USD, decreased -11.96 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aldeyra Therapeutics Inc (ALDX)'s fundamentals?

The market is revising No Change the revenue expectations for Aldeyra Therapeutics, Inc. (ALDX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -12.23%.
arrow icon

How many employees does Aldeyra Therapeutics Inc (ALDX). have?

Aldeyra Therapeutics Inc (ALDX) has 9 emplpoyees as of December 05 2025.

arrow icon

What is Aldeyra Therapeutics Inc (ALDX) market cap?

Today ALDX has the market capitalization of 293.59M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free